RxDoctor Payments Data

Chester Hedgepeth, MD

Cardiovascular Disease · Brockton, MANPI 1063409233

Payments from drug & device makers

$85,688in general payments, 2019–2025

Across 29 payments — averaging $2954.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$24K
  • Amgen$23K
  • Bayer$20K
  • Sanofi US Services Inc.$10K
  • AstraZeneca$9K

What the payments were for

  • Food & beverage$42100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis3$24,108
Amgen16$22,942
Bayer5$19,893
Sanofi US Services Inc.3$9,680
AstraZeneca2$9,065

How this compares

$85,688 in reported general payments places this provider in the 85th percentile of 750 cardiovascular disease providers in Massachusetts.

See all cardiovascular disease providers in Massachusetts

Medicare billing

Part B allowed, 2024
$92,034
Medicare patients
1,291
Services billed
2,178

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban469$374,256
XareltoRivaroxaban205$178,693
EntrestoSacubitril/Valsartan54$46,302
Repatha SureclickEvolocumab54$32,814
JardianceEmpagliflozin55$32,393
BrilintaTicagrelor32$23,857
Praluent PenAlirocumab21$14,552
FarxigaDapagliflozin Propanediol18$10,237
Metoprolol Succinate591$8,551
Dabigatran EtexilateDabigatran Etexilate Mesylate40$7,324
Diltiazem 24hr Er (Cd)Diltiazem Hcl139$3,954
Atorvastatin Calcium261$3,002
Diltiazem 24hr Er (La)Diltiazem Hcl19$2,652
Dofetilide14$2,627
Furosemide273$2,048

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$24,108$46,30254 claims
AstraZenecaBrilinta, Farxiga$9,065$34,09450 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 750 cardiovascular disease providers in Massachusetts.

Other cardiovascular disease in Brockton

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →